Invitae issued approximately $21.2 million in shares of its own common stock to former CombiMatrix shareholders.
The company said the planned commercial launch of its noninvasive lung cancer diagnostic has been delayed due to technical issues during the test's validation process.
Investigators have established hundreds of patient-derived xenografts, cell lines, and tumor samples, which appear to represent a wide range of melanoma molecular subtypes.
The companies will use Ymir's urine extracellular vesicle technology and OHSU's Proteomics Shared Resource to develop biomarkers for hepatocellular carcinoma.
The company will use the funds to expand its US-based business and to commercialize its data visualization platform.
Harvard Bioscience will offer Fluxion's BioFlux and IonFlux cellular analysis platforms to its North American customers.
The partners plan to validate blood-based microRNAs as biomarkers for the early detection of pulmonary and neurodegenerative diseases.
Syapse has raised new venture capital to support expansion into community hospitals that want to start precision oncology programs.
Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.
Paris-based Scipio will use the seed funding to further develop and commercialize its first prototype kit for single-cell transcriptomics.
The alliance follows a marketing deal signed with Sysmex Europe that covers Europe, the Middle East, and Africa.
The grant was awarded under a program designed to help small businesses transition NIH-funded projects into the commercialization stage.
The offering was a follow-on to a capital raise during the summer that brought in $6 million. The company's CEO said the additional financing was needed to execute on its business plan.
The MIT-led team that developed the delivery technique said that it was able to induce more than 80 percent editing of the Pcsk9 gene in the livers of mice.
Using an integrated omics approach, researchers identified non-muscle invasive bladder cancer subtypes, along with pathways that are frequently altered in the disease.
The company's ThyGenX and ThyraMir tests are designed for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.
Last week, GenomeWeb's readers were most interested in the UK's NHS preparing to provide WGS as a routine diagnostic test for certain rare diseases and cancers.
In a study of nearly 45,000 people, researchers found that two variants in LPA each increase aortic stenosis risk by about a third, and about twofold in combination.
A tumor sequencing study suggests the retention or deletion of interstitial genes within the TMPRSS2-ERG gene fusion may coincide with prostate cancer progression.
The IP is based on the research of Emmanuelle Charpentier from the Hannover Medical School in Germany and Umea University in Sweden.
The $12 million PRIME study will involve 2,000 veterans with major depressive disorder and 250 healthcare providers across 21 VA medical centers.
The company fell short of the consensus Wall Street revenue estimate, while its net loss for the quarter also widened.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.
CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.
In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.